Debate: Transplant vs. CAR T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Educating clinicians about the recent clinical advances and the benefits/risks associated with the use of transplant and CAR T-cell therapy can help them to make informed clinical decisions for individual patients.
Category
  • Non-Hodgkin's Lymphoma
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
ECHELON-1: Do Updated Results Change the First-Line Treatment of Stage III-IV Classical Hodgkin Lymphoma?
An awareness of the updated safety and efficacy results from the ECHELON-1 trial will help clinicians determine how to optimally incorporate BV-AVD regimen as fist-line therapy in appropriately selected patients with stage III-IV classical Hodgkin lymphoma.
Category
  • Hodgkin Lymphoma
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Management of Advanced Systemic Mastocytosis
It is critically important for oncology care providers to be aware of the best ways to incorporate these advances into standard practice so that each patient can receive optimal care.
Category
  • Systemic Mastocytosis
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Familial/Genetic Leukemia Syndromes: Impact on Patient Care
Clinicians need education regarding which patients with leukemia are candidates for genetic counseling and testing and how the management of patients with known germline mutations is affected. This knowledge will help clinicians provide these patients with optimal care.
Category
  • Acute Lymphoblastic Leukemia
  • Acute Myelogenous Leukemia
  • Chronic Myelogenous Leukemia
  • Leukemia
Format
  • Recorded Webcast
Credits
  • 0.75 AAPA Category 1 CME credit
  • 0.75 ACPE contact hours
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 ANCC contact hours
  • 0.75 Participation
Hematopoietic Growth Factors: Use of Thrombopoietin Receptor Agonists in Patients with Cancer
Since there is currently no FDA-approved treatment for CIT, clinicians must make decisions on the appropriate incorporation of thrombopoietin receptor agonists (TPO-RAs) into clinical practice. Increased education and awareness of the available treatment options, including TPO-RA, will help to ensure the acceptance and use of these agents in supportive oncology care for patients with CIT.
Category
  • Myeloid Growth Factors
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Management of Chronic Phase Chronic Myeloid Leukemia with Resistance to Multiple TKIs
In the majority of patients responding to TKI therapy, chronic myeloid leukemia (CML) is now managed like a chronic disease. However, it poses significant challenges to the clinicians in terms of selection of alternate TKI therapy in patients with inadequate initial response to initial TKI therapy. Informing clinicians about the recent FDA approvals would assist in the incorporation of new treatment options into their routine clinical practice to improve patient outcomes.
Category
  • Chronic Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Managing Cardiovascular Events in Multiple Myeloma
With careful risk assessment, monitoring, and prophylactic treatment, the cardiovascular adverse events associated with multiple myeloma (MM) treatments can be prevented or identified and managed at an early stage. To optimize the management of patients with multiple myeloma and cardiac comorbidities, it is important for clinicians to learn how to recognize these risks and implement appropriate management strategies.
Category
  • Multiple Myeloma
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Emerging Treatment Options for Myelodysplastic Syndromes
Clinicians should be aware of emerging data in the field so they can decide on how to best incorporate novel strategies in a patient’s treatment plan.
Category
  • Myelodysplastic Syndromes
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Management of Polycythemia Vera and Essential Thrombocythemia
It is important for physicians to stay up to date on treatment recommendations so they can best evaluate available data and select the optimal therapeutic strategy based on the patient’s clinical needs. 
Category
  • Myeloproliferative Neoplasms
Format
  • Recorded Webcast
Credits
  • 0.50 AAPA Category 1 CME credit
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.50 ANCC contact hours
  • 0.50 Participation
Archived Monthly Oncology Tumor Boards: Management of Early Stage Breast Cancer
Being familiar with the current management of breast cancer will help clinicians support their patients and to communicate with specialists in the multidisciplinary team.
Category
  • Breast Cancer
Format
  • Recorded Webcast
Credits
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation

Pages